Eli Lilly & Co.'s bid for accelerated approval of its Alzheimer's therapy donanemab was rejected by U.S. regulators, an unexpected setback for the drugmaker.The Food and Drug Administration sent the company a complete response letter saying it would not give the early approval for the drug because not enough patients on the trial had received it for a full 12 months, Lilly said Thursday in a statement.
[
Collection
]
[
|
...
]